The significant surge in iBio Inc's stock price is directly attributed to the announcement of a promising collaboration with AstralBio. This partnership not only brings financial investment into iBio but also leverages iBio's AI technology for developing treatments for obesity and cardiometabolic diseases, areas with high demand for innovative solutions. The positive market reaction reflects investor optimism about the potential of this collaboration to generate valuable intellectual property and future revenue streams for iBio.